Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combined chemotherapy and radiation therapy for CNS germ cell tumors - theJapanese experience
Autore:
Matsutani, M;
Indirizzi:
Saitama Med Sch, Dept Neurosurg, Moroyama, Saitama 35004, Japan Saitama Med Sch Moroyama Saitama Japan 35004 royama, Saitama 35004, Japan
Titolo Testata:
JOURNAL OF NEURO-ONCOLOGY
fascicolo: 3, volume: 54, anno: 2001,
pagine: 311 - 316
SICI:
0167-594X(2001)54:3<311:CCARTF>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
MALIGNANT TERATOMA; GERMINOMA; IRRADIATION; CISPLATIN; CHILDHOOD;
Keywords:
brain tumor; germ cell tumor; radiation therapy; chemotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Matsutani, M Saitama Med Sch, Dept Neurosurg, Morohongo 38, Moroyama, Saitama 35004, Japan Saitama Med Sch Morohongo 38 Moroyama Saitama Japan 35004 pan
Citazione:
M. Matsutani, "Combined chemotherapy and radiation therapy for CNS germ cell tumors - theJapanese experience", J NEURO-ONC, 54(3), 2001, pp. 311-316

Abstract

Among intracranial germ cell tumors, nongerminomatous tumors have proved refractory to conventional treatment with surgery and irradiation. The median survival is less than 2 years. Since 1983, chemotherapy has been delivered in Japan as an adjuvant therapy in patients with intracranial nongerminomatous germ cell tumors. Based on our clinical experience, we undertook a multi-institutional phase II study to establish post-surgical combined chemotherapy and radiation therapy for primary germ cell tumors in the brain. We adopted carboplatin-etoposide (CARB-VP) or cisplatin-etoposide (PE) combination chemotherapy for patients with germinomas and those with tumors that placed them in the intermediate prognosis group, and ifosphamide-cisplatin-etoposide (ICE) for patients with tumors that placed them in the poor prognosis group. One hundred and twelve patients were evaluated. Among patients with germinoma (n = 75), the rate or complete remission after combination therapy was 92.0%; it was 67.8% for patients in the intermediate prognosis group (n = 28). Tumor recurrence was noted in 9 patients with germinoma and 2patients in the intermediate prognosis group. Of 9 patients with a poor prognosis, 4 experienced disease progression during treatment and died within10 months. There were no serious complications attributable to the combination therapy. Our treatment protocols are effective for patients with germinomas and those with an intermediate prognosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 05:20:13